CD45 Antibody (YAML 501.4): sc-65344

CD45 Antibody (YAML 501.4) is a rat monoclonal IgG2a antibody engineered to target CD45 protein, also known as Protein Tyrosine Phosphatase Receptor Type C (PTPRC). CD45 is a vital transmembrane glycoprotein expressed on the surface of all nucleated hematopoietic cells in humans, playing a crucial role in regulating immune cell signaling and activation. Located on the cell membrane, CD45 functions as a phosphotyrosine phosphatase, modulating key signal transduction pathways by dephosphorylating tyrosine residues on Src family kinases such as Lck and Fyn, as well as on Syk family kinases like ZAP-70. These interactions are essential for proper T and B cell receptor signaling, influencing lymphocyte development, activation, and overall immune responses. The strategic localization of CD45 on the cell surface allows effective interaction with these kinases, thereby controlling the initiation and propagation of signaling cascades that are fundamental to immune system function. CD45 undergoes significant post-translational modifications, including glycosylation, which are critical for stability, membrane localization, and interaction with other signaling molecules, enhancing regulatory capabilities. Anti-CD45 antibody (YAML 501.4) is raised against acute myeloid leukemia cells of human origin, ensuring effective detection in various applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). By targeting CD45, CD45 monoclonal antibody (YAML 501.4) facilitates comprehensive analysis of immune cell populations and their signaling mechanisms, making this tool indispensable for both research and diagnostic purposes in immunology and hematology.

The preferred CD45 antibody is CD45 Antibody (35-Z6): sc-1178.